Patents by Inventor Thomas Giller
Thomas Giller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230051321Abstract: Disclosed are non-aqueous solid and liquid compositions comprising resiniferatoxin and a surfactant. The non-aqueous solid and liquid compositions may be used to prepare aqueous compositions that are used in the treatment of pain, specifically osteoarthritis-related joint pain. Moreover, also disclosed are kits containing the non-aqueous solid and liquid compositions and a diluent and methods of preparing the compositions. The non-aqueous solid and liquid compositions allow for longer storage and recovery of resiniferatoxin compared to resiniferatoxin alone prior to reconstitution with a diluent.Type: ApplicationFiled: October 17, 2022Publication date: February 16, 2023Applicant: GRUENENTHAL GMBHInventors: Andreas BERNKOP-SCHNUERCH, Olivier VALDENAIRE, Thomas GILLER
-
Publication number: 20220008384Abstract: A composition comprising capsaicin or a capsacinoid is used in a method for postoperative pain control. The composition is administered to a site intended for surgery in a patient at least one day before surgery is actually performed.Type: ApplicationFiled: September 27, 2021Publication date: January 13, 2022Applicant: MESTEX AGInventors: Christian GERBER, Thomas GILLER, Olivier VALDENAIRE
-
Publication number: 20170210540Abstract: A packaging for edge-sensitive cargo. The abstract of the disclosure is submitted herewith as required by 37 C.F.R. §1.72(b). As stated in 37 C.F.R. §1.72(b): A brief abstract of the technical disclosure in the specification must commence on a separate sheet, preferably following the claims, under the heading “Abstract of the Disclosure.” The purpose of the abstract is to enable the Patent and Trademark Office and the public generally to determine quickly from a cursory inspection the nature and gist of the technical disclosure. The abstract shall not be used for interpreting the scope of the claims. Therefore, any statements made relating to the abstract are not intended to limit the claims in any manner and should not be interpreted as limiting the claims in any manner.Type: ApplicationFiled: March 21, 2017Publication date: July 27, 2017Inventor: Thomas GILLER
-
Patent number: 9598217Abstract: A packaging for edge-sensitive cargo. The abstract of the disclosure is submitted herewith as required by 37 C.F.R. §1.72(b). As stated in 37 C.F.R. §1.72(b): A brief abstract of the technical disclosure in the specification must commence on a separate sheet, preferably following the claims, under the heading “Abstract of the Disclosure.” The purpose of the abstract is to enable the Patent and Trademark Office and the public generally to determine quickly from a cursory inspection the nature and gist of the technical disclosure. The abstract shall not be used for interpreting the scope of the claims. Therefore, any statements made relating to the abstract are not intended to limit the claims in any manner and should not be interpreted as limiting the claims in any manner.Type: GrantFiled: March 27, 2015Date of Patent: March 21, 2017Inventor: Thomas Giller
-
Publication number: 20150298885Abstract: A packaging for edge-sensitive cargo. The abstract of the disclosure is submitted herewith as required by 37 C.F.R. §1.72(b). As stated in 37 C.F.R. §1.72(b): A brief abstract of the technical disclosure in the specification must commence on a separate sheet, preferably following the claims, under the heading “Abstract of the Disclosure.” The purpose of the abstract is to enable the Patent and Trademark Office and the public generally to determine quickly from a cursory inspection the nature and gist of the technical disclosure. The abstract shall not be used for interpreting the scope of the claims. Therefore, any statements made relating to the abstract are not intended to limit the claims in any manner and should not be interpreted as limiting the claims in any manner.Type: ApplicationFiled: March 27, 2015Publication date: October 22, 2015Inventor: Thomas GILLER
-
Publication number: 20150190509Abstract: The invention relates to a resiniferatoxin solution having an enhanced storage stability, in which the resiniferatoxin is dissolved in a body-compatible solvent which contains a protective gas in solution, wherein the amount of the protective gas is at least 1 wt % of the saturation amount of the protective gas in the solvent at ambient temperature and normal pressure. The resiniferatoxin dissolved in the resiniferatoxin solution remains stable for a relatively long period and exhibits a reduced tendency to cling to polymeric surfaces.Type: ApplicationFiled: August 3, 2012Publication date: July 9, 2015Applicant: MESTEX AGInventor: Thomas Giller
-
Patent number: 7727979Abstract: The invention relates to guanidine derivatives of formula (I) where: A represents a chain of 3-6 carbon atoms, one of which can be replaced by —N(R?)— or —O— and R? is H or a substituent; the ring skeleton only contains both double bonds of the thiazole component; the pharmaceutically-acceptable acid addition salts of basic compounds of formula (I), the pharmaceutically-acceptable salts of compounds of formula (I), comprising acid groups, with bases, the pharmaceutically-acceptable esters of hydroxy or carboxyl group containing compounds of formula (I) and the solvates or hydrates thereof, which exhibit a neuropeptide FF receptor antagonist effect. The above are suitable for the treatment of pain and hyperalgesia, withdrawal symptoms in alcohol, psychotropic and nicotine dependencies, for improvement or cure of said dependencies, for regulation of insulin excretion, food intake, memory functions, blood pressure, electrolyte and energy management and for treatment of urinary incontinence.Type: GrantFiled: March 22, 2004Date of Patent: June 1, 2010Assignee: Actelion Pharmaceuticals Ltd.Inventors: Eva Caroff, Matthias Steger, Oliver Valdenaire, Anja Fecher, Volker Breu, Kurt Hilpert, Heinz Fretz, Thomas Giller
-
Patent number: 7544691Abstract: The invention relates to the guanine derivatives of general formula (I), and to hydrates or solvents thereof, for use as neuropeptide FF receptor antagonists in the treatment of pains and hyperalgesia, of withdrawal symptoms of addiction to alcohol, psychotropic drugs or nicotine and in the prevention of or recovery from these addictions, for the regulation of insulin release, food intake, memory functions, blood pressure, electrolyte and energy metabolism, and in the treatment of urinary incontinenceType: GrantFiled: September 3, 2004Date of Patent: June 9, 2009Assignee: Actelion Pharmaceuticals, Ltd.Inventors: Volker Breu, Anja Fecher, Heinz Fretz, Thomas Giller, Kurt Hilpert, Olivier Valdenaire
-
Publication number: 20070123510Abstract: The invention relates to the guanine derivatives of general formula (I), and to hydrates or solvents thereof, for use as neuropeptide FF receptor antagonists in the treatment of pains and hyperalgesia, of withdrawal symptoms of addiction to alcohol, psychotropic drugs or nicotine and in the prevention of or recovery from these addictions, for the regulation of insulin release, food intake, memory functions, blood pressure, electrolyte and energy metabolism, and in the treatment of urinary incontinence.Type: ApplicationFiled: September 3, 2004Publication date: May 31, 2007Applicant: ACTELION PHARMACEUTICALS LTD.Inventors: Volker Breu, Anja Fecher, Heinz Fretz, Thomas Giller, Kurt Hilpert, Olivier Valdenaire
-
Publication number: 20070037846Abstract: The present invention relates to compounds of alkylidene pyrazolidinedione derivatives, which are effective platelet ADP receptor antagonists that prevent platelet aggregation and thrombosis. Thus, the present invention also relates to pharmaceutical compositions that contain the compounds as well as methods of preventing or treating peripheral, visceral, hepatic, renal, cardio- and cerebro-vascular diseases and conditions that are associated with platelet aggregation, including thrombosis, in humans and other mammals. The present invention further provides a process for manufacturing the alkylidene pyrazolidinedione derivatives.Type: ApplicationFiled: June 16, 2004Publication date: February 15, 2007Applicant: ACTELION PHARMACEUTICALS, LTD.Inventors: Heinz Fretz, Thomas Giller, Kurt Hilpert, Olivier Houille, Markus Riederer, Oliver Valdenaire
-
Publication number: 20060194788Abstract: The invention relates to guanidine derivatives of formula (I) where: A represents a chain of 3-6 carbon atoms, one of which can be replaced by —N(R?)— or —O— and R? is H or a substituent; the ring skeleton only contains both double bonds of the thiazole component; the pharmaceutically-acceptable acid addition salts of basic compounds of formula (I), the pharmaceutically-acceptable salts of compounds of formula (I), comprising acid groups, with bases, the pharmaceutically-acceptable esters of hydroxy or carboxyl group containing compounds of formula (I) and the solvates or hydrates thereof, which exhibit a neuropeptide FF receptor antagonist effect. The above are suitable for the treatment of pain and hyperalgesia, withdrawal symptoms in alcohol, psychotropic and nicotine dependencies, for improvement or cure of said dependencies, for regulation of insulin excretion, food intake, memory functions, blood pressure, electrolyte and energy management and for treatment of urinary incontinence.Type: ApplicationFiled: March 22, 2004Publication date: August 31, 2006Inventors: Eva Caroff, Matthias Steger, Oliver Valdenaire, Anja Fecher, Volker Breu, Kurt Hilpert, Heinz Fretz, Thomas Giller
-
Patent number: 7067549Abstract: Pyrrolidone carboxamides of formula (I) where R2=a group of formula (a) or (b), R5=phenyl, heteroalkyl, aryloxy, alkoxy, alkanoyl or —NR6R7 and R1, X, R3, R4, R6 and R7 have the meanings given in the description and the claims, pharmaceutically applicable acid addition salts with basic compounds of formula (I), pharmaceutically applicable salts of acid compounds of formula (I) with bases, pharmaceutically applicable esters of hydroxy- or carboxy-group containing compounds of formula (I) and hydrates and solvates thereof, inhibit the interaction of neuropeptide Y (NPY) with one of the neuropeptide receptor subtypes (NPY-Y5) and are particularly suitable for the prevention and treatment of arthritis, diabetes and especially eating disorders and obesity. The above can be produced by known methods and converted into a galenic dosage form.Type: GrantFiled: December 27, 2002Date of Patent: June 27, 2006Assignee: Actelion Pharmaceuticals AGInventors: Markus Isler, Thomas Giller, Günter Schwalm, Matthias Steger, Kurt Hilpert, Oliver Valdenaire, Volker Breu
-
Publication number: 20050192292Abstract: Pyrrolidone carboxamides of formula (I) where R2=a group of formula (a) or (b), R5=phenyl, heteroalkyl, aryloxy, alkoxy, alkanoyl or —NR6R7 and R1, X, R3, R4, R6 and R7 have the meanings given in the description and the claims, pharmaceutically applicable acid addition salts with basic compounds of formula (I), pharmaceutically applicable salts of acid compounds of formula (I) with bases, pharmaceutically applicable esters of hydroxy- or carboxy-group containing compounds of formula (I) and hydrates and solvates thereof, inhibit the interaction of neuropeptide Y (NPY) with one of the neuropeptide receptor subtypes (NPY-Y5) and are particularly suitable for the prevention and treatment of arthritis, diabetes and especially eating disorders and obesity. The above can be produced by known methods and converted into a galenic dosage form.Type: ApplicationFiled: December 27, 2002Publication date: September 1, 2005Inventors: Markus Isler, Thomas Giller, Gunter Schwaim, Matthias Steger, Kurt Hilpert, Oliver Valdenaire, Volker Breu